Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Moderna's MRNA-1647?
MRNA-1647 is a mrna vaccine commercialized by Moderna, with a leading Phase III program in Cytomegalovirus (HHV-5) Infections. According to...
Data Insights
Risk adjusted net present value: What is the current valuation of Moderna's MRNA-1647?
MRNA-1647 is a mrna vaccine commercialized by Moderna, with a leading Phase III program in Cytomegalovirus (HHV-5) Infections. According to...